{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+I+Hepatocellular+Carcinoma+AJCC+v8",
    "query": {
      "condition": "Stage I Hepatocellular Carcinoma AJCC v8"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+I+Hepatocellular+Carcinoma+AJCC+v8&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:08:44.870Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02595866",
      "title": "Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AIDS-Related Non-Hodgkin Lymphoma",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Hepatocellular Carcinoma",
        "HIV Infection",
        "Kaposi Sarcoma",
        "Locally Advanced Lung Non-Small Cell Carcinoma",
        "Locally Advanced Malignant Solid Neoplasm",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Non-Hodgkin Lymphoma",
        "Recurrent Classic Hodgkin Lymphoma",
        "Recurrent Malignant Neoplasm",
        "Refractory Classic Hodgkin Lymphoma",
        "Refractory Malignant Neoplasm",
        "Stage III Lung Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Antiretroviral Therapy",
          "type": "DRUG"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2016-04-04",
      "completion_date": "2024-03-25",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-05-22T05:08:44.870Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02595866"
    },
    {
      "nct_id": "NCT05194293",
      "title": "Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IB Hepatocellular Carcinoma AJCC v8",
        "Stage II Hepatocellular Carcinoma AJCC v8",
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage IIIA Hepatocellular Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Regorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2023-07-01",
      "completion_date": "2028-12-05",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-05-22T05:08:44.870Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05194293"
    },
    {
      "nct_id": "NCT05269381",
      "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage III Merkel Cell Carcinoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IV Merkel Cell Carcinoma AJCC v8",
        "Clinical Stage IVA Gastric Cancer AJCC v8",
        "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IVB Gastric Cancer AJCC v8",
        "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Locally Advanced Cervical Carcinoma",
        "Locally Advanced Endometrial Carcinoma",
        "Locally Advanced Gastric Adenocarcinoma",
        "Locally Advanced Gastroesophageal Junction Adenocarcinoma",
        "Locally Advanced Head and Neck Squamous Cell Carcinoma",
        "Locally Advanced Hepatocellular Carcinoma",
        "Locally Advanced Lung Non-Small Cell Carcinoma",
        "Locally Advanced Malignant Solid Neoplasm",
        "Locally Advanced Melanoma",
        "Locally Advanced Merkel Cell Carcinoma",
        "Locally Advanced Renal Cell Carcinoma",
        "Locally Advanced Skin Squamous Cell Carcinoma",
        "Locally Advanced Triple-Negative Breast Carcinoma",
        "Locally Advanced Unresectable Breast Carcinoma",
        "Locally Advanced Unresectable Cervical Carcinoma",
        "Locally Advanced Unresectable Gastric Adenocarcinoma",
        "Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma",
        "Locally Advanced Unresectable Renal Cell Carcinoma",
        "Locally Advanced Urothelial Carcinoma",
        "Metastatic Cervical Carcinoma",
        "Metastatic Endometrial Carcinoma",
        "Metastatic Gastric Adenocarcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Hepatocellular Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Metastatic Merkel Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Metastatic Skin Squamous Cell Carcinoma",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Skin Squamous Cell Carcinoma",
        "Stage III Cervical Cancer AJCC v8",
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IIIA Cervical Cancer AJCC v8",
        "Stage IIIA Hepatocellular Carcinoma AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIA Uterine Corpus Cancer AJCC v8",
        "Stage IIIB Cervical Cancer AJCC v8",
        "Stage IIIB Hepatocellular Carcinoma AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIB Uterine Corpus Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IIIC Uterine Corpus Cancer AJCC v8",
        "Stage IIIC1 Uterine Corpus Cancer AJCC v8",
        "Stage IIIC2 Uterine Corpus Cancer AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IVA Cervical Cancer AJCC v8",
        "Stage IVA Hepatocellular Carcinoma AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVA Uterine Corpus Cancer AJCC v8",
        "Stage IVB Cervical Cancer AJCC v8",
        "Stage IVB Hepatocellular Carcinoma AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Stage IVB Uterine Corpus Cancer AJCC v8",
        "Triple-Negative Breast Carcinoma",
        "Unresectable Cervical Carcinoma",
        "Unresectable Endometrial Carcinoma",
        "Unresectable Gastric Adenocarcinoma",
        "Unresectable Gastroesophageal Junction Adenocarcinoma",
        "Unresectable Head and Neck Squamous Cell Carcinoma",
        "Unresectable Hepatocellular Carcinoma",
        "Unresectable Lung Non-Small Cell Carcinoma",
        "Unresectable Malignant Solid Neoplasm",
        "Unresectable Melanoma",
        "Unresectable Merkel Cell Carcinoma",
        "Unresectable Renal Cell Carcinoma",
        "Unresectable Skin Squamous Cell Carcinoma",
        "Unresectable Triple-Negative Breast Carcinoma",
        "Unresectable Urothelial Carcinoma",
        "Breast Adenocarcinoma",
        "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Neoantigen Peptide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2022-03-31",
      "completion_date": "2028-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-05-22T05:08:44.870Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05269381"
    },
    {
      "nct_id": "NCT06811116",
      "title": "Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Hepatocellular Carcinoma",
        "Metastatic Hepatocellular Carcinoma",
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Imaging Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2025-11-17",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T05:08:44.870Z",
      "location_count": 4,
      "location_summary": "Irvine, California • Orange, California • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06811116"
    },
    {
      "nct_id": "NCT06968195",
      "title": "Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Hepatocellular Carcinoma",
        "Metastatic Hepatocellular Carcinoma",
        "Recurrent Hepatocellular Carcinoma",
        "Refractory Hepatocellular Carcinoma",
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Anti-GPC3-CAR Autologous T Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2026-05-01",
      "completion_date": "2029-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-05-22T05:08:44.870Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06968195"
    },
    {
      "nct_id": "NCT04785287",
      "title": "Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lung Carcinoma",
        "Advanced Malignant Solid Neoplasm",
        "Malignant Adrenal Gland Neoplasm",
        "Metastatic Liver Carcinoma",
        "Metastatic Lung Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Stage III Liver Cancer",
        "Stage III Lung Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Liver Cancer",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Liver Cancer",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Liver Cancer",
        "Stage IVB Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Anti-CTLA4 Monoclonal Antibody BMS-986218",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2021-03-29",
      "completion_date": "2026-02-26",
      "has_results": false,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-05-22T05:08:44.870Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04785287"
    },
    {
      "nct_id": "NCT03695250",
      "title": "BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Hepatocellular Carcinoma",
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage IIIA Hepatocellular Carcinoma AJCC v8",
        "Stage IIIB Hepatocellular Carcinoma AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IVA Hepatocellular Carcinoma AJCC v8",
        "Stage IVB Hepatocellular Carcinoma AJCC v8",
        "Unresectable Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "IDO1 Inhibitor BMS-986205",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Edward Kim",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2018-10-16",
      "completion_date": "2021-03-12",
      "has_results": true,
      "last_update_posted_date": "2023-08-22",
      "last_synced_at": "2026-05-22T05:08:44.870Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03695250"
    },
    {
      "nct_id": "NCT05092373",
      "title": "Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Breast Carcinoma",
        "Advanced Endometrial Carcinoma",
        "Advanced Fallopian Tube Carcinoma",
        "Advanced Hepatocellular Carcinoma",
        "Advanced Malignant Abdominal Neoplasm",
        "Advanced Malignant Female Reproductive System Neoplasm",
        "Advanced Malignant Thoracic Neoplasm",
        "Advanced Ovarian Carcinoma",
        "Advanced Primary Peritoneal Carcinoma",
        "Advanced Renal Cell Carcinoma",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Malignant Abdominal Neoplasm",
        "Malignant Solid Neoplasm",
        "Metastatic Breast Carcinoma",
        "Metastatic Endometrial Carcinoma",
        "Metastatic Fallopian Tube Carcinoma",
        "Metastatic Hepatocellular Carcinoma",
        "Metastatic Malignant Abdominal Neoplasm",
        "Metastatic Malignant Female Reproductive System Neoplasm",
        "Metastatic Malignant Thoracic Neoplasm",
        "Metastatic Ovarian Carcinoma",
        "Metastatic Primary Peritoneal Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Prognostic Stage III Breast Cancer AJCC v8",
        "Prognostic Stage IIIA Breast Cancer AJCC v8",
        "Prognostic Stage IIIB Breast Cancer AJCC v8",
        "Prognostic Stage IIIC Breast Cancer AJCC v8",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Stage III Fallopian Tube Cancer AJCC v8",
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Primary Peritoneal Cancer AJCC v8",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage III Uterine Corpus Cancer AJCC v8",
        "Stage IIIA Fallopian Tube Cancer AJCC v8",
        "Stage IIIA Hepatocellular Carcinoma AJCC v8",
        "Stage IIIA Ovarian Cancer AJCC v8",
        "Stage IIIA Primary Peritoneal Cancer AJCC v8",
        "Stage IIIA Uterine Corpus Cancer AJCC v8",
        "Stage IIIA1 Fallopian Tube Cancer AJCC v8",
        "Stage IIIA1 Ovarian Cancer AJCC v8",
        "Stage IIIA2 Fallopian Tube Cancer AJCC v8",
        "Stage IIIA2 Ovarian Cancer AJCC v8",
        "Stage IIIB Fallopian Tube Cancer AJCC v8",
        "Stage IIIB Hepatocellular Carcinoma AJCC v8",
        "Stage IIIB Ovarian Cancer AJCC v8",
        "Stage IIIB Primary Peritoneal Cancer AJCC v8",
        "Stage IIIB Uterine Corpus Cancer AJCC v8",
        "Stage IIIC Fallopian Tube Cancer AJCC v8",
        "Stage IIIC Ovarian Cancer AJCC v8",
        "Stage IIIC Primary Peritoneal Cancer AJCC v8",
        "Stage IIIC Uterine Corpus Cancer AJCC v8",
        "Stage IIIC1 Uterine Corpus Cancer AJCC v8",
        "Stage IIIC2 Uterine Corpus Cancer AJCC v8",
        "Stage IV Fallopian Tube Cancer AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Primary Peritoneal Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IV Uterine Corpus Cancer AJCC v8",
        "Stage IVA Fallopian Tube Cancer AJCC v8",
        "Stage IVA Hepatocellular Carcinoma AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Primary Peritoneal Cancer AJCC v8",
        "Stage IVA Uterine Corpus Cancer AJCC v8",
        "Stage IVB Fallopian Tube Cancer AJCC v8",
        "Stage IVB Hepatocellular Carcinoma AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Primary Peritoneal Cancer AJCC v8",
        "Stage IVB Uterine Corpus Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Tumor Treating Fields Therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2022-04-29",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-05-22T05:08:44.870Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05092373"
    },
    {
      "nct_id": "NCT04805788",
      "title": "Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Hepatocellular Carcinoma",
        "Stage I Hepatocellular Carcinoma AJCC v8",
        "Stage II Hepatocellular Carcinoma AJCC v8",
        "Stage III Hepatocellular Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Proton Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2021-08-24",
      "completion_date": "2025-01-28",
      "has_results": false,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-05-22T05:08:44.870Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04805788"
    },
    {
      "nct_id": "NCT04721132",
      "title": "Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Resectable Hepatocellular Carcinoma",
        "Stage I Hepatocellular Carcinoma AJCC v8",
        "Stage IA Hepatocellular Carcinoma AJCC v8",
        "Stage IB Hepatocellular Carcinoma AJCC v8",
        "Stage II Hepatocellular Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2021-02-10",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-05-22T05:08:44.870Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04721132"
    }
  ]
}